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Background: The Project on a Framework for Rating Evidence in Public Health (PRECEPT) was initiated and is being
funded by the European Centre for Disease Prevention and Control (ECDC) to define a methodology for evaluating
and grading evidence and strength of recommendations in the field of public health, with emphasis on infectious
disease epidemiology, prevention and control. One of the first steps was to review existing quality appraisal tools
(QATs) for individual research studies of various designs relevant to this area, using a question-based approach.
Methods: Through team discussions and expert consultations, we identified 20 relevant types of public health
questions, which were grouped into six domains, i.e. characteristics of the pathogen, burden of disease, diagnosis,
risk factors, intervention, and implementation of intervention. Previously published systematic reviews were used
and supplemented by expert consultation to identify suitable QATs. Finally, a matrix was constructed for matching
questions to study designs suitable to address them and respective QATs. Key features of each of the included
QATs were then analyzed, in particular in respect to its intended use, types of questions and answers, presence/
absence of a quality score, and if a validation was performed.
Results: In total we identified 21 QATs and 26 study designs, and matched them. Four QATs were suitable for
experimental quantitative study designs, eleven for observational quantitative studies, two for qualitative studies,
three for economic studies, one for diagnostic test accuracy studies, and one for animal studies. Included QATs
consisted of six to 28 items. Six of the QATs had a summary quality score. Fourteen QATs had undergone at least
one validation procedure.
Conclusions: The results of this methodological study can be used as an inventory of potentially relevant
questions, appropriate study designs and QATs for researchers and authorities engaged with evidence-based
decision-making in infectious disease epidemiology, prevention and control.
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Evidence-based medicine and evidence-based public health
The fallacies of relying solely on expert opinion to estab-
lish best practice in clinical decision-making and public
health policies are now well exposed globally [1,2]. It is
now standard practice in guideline development to draw
on systematic reviews. With regard to interventions, ran-
domized controlled trials (RCTs) are the gold standard
due to their capacity to minimize bias, if well conducted.
Systematic reviews of RCTs are therefore commonly
used in decision-making. However, many questions that
play an important role in decision-making –especially
those not directly concerning the effectiveness and safety
of an intervention– have not been and partly cannot be
addressed by RCTs, and evidence from well-conducted
observational studies becomes important for decision-
making. Particularly in public health quasi-experimental
designs have been used to evaluate population-level
effects, such as controlled before-and-after studies,
stepped wedge designs, and interrupted time series. In
areas for which well conducted experimental trials are
missing and pressure exists to make decisions in due
time, guidance developers and decision-makers need to
rely on the best available evidence, and guidance is
needed on how to select and critically appraise different
types of evidence to support rigorous and transparent
decision-making [3].
In infectious disease prevention and control, special-
ists also need to consider what consequences a public
health intervention might have at population level [4-7],
e.g. on spread of a pathogen in the total population. In
the context of developing recommendations for infec-
tious disease prevention and control in particular, sev-
eral relevant questions cannot (easily) be addressed by
RCTs. Challenges include assessing population-level ef-
fects (e.g. serotype-replacement following vaccine intro-
duction, development of antibiotic resistance, or herd
protection through reduced pathogen transmission) and
long-term aspects of the intervention (e.g. the need for
a booster vaccination ten years after primary vaccin-
ation), but also data on the disease burden in a given
population, cost-of-illness, risk factors for infection or
increased disease severity, or the mode of transmission
of a newly recognized disease or during a nosocomial
outbreak. Therefore, evidence informing these poten-
tially relevant questions needs to take into account
summaries from different sorts of research, including
case-control studies, incidence studies, passively col-
lected surveillance data, case series, outbreak investiga-
tions, and single case reports. In adopting the idea of
“best available evidence” [6], tracing the full causal chain
from intervention to outcomes within a given context
requires a variety of fit-for-purpose methods from mul-
tiple disciplines.The PRECEPT approach
More recently developed evidence appraisal and grading
systems are designed to incorporate information from
studies with different designs, including RCTs as well as
observational studies. The most prominent system de-
veloped by the Grading of Recommendations Assess-
ment, Development and Evaluation Working Group
(GRADE) [8,9] has already been widely applied not only
in clinical medicine, but also in the context of public
health interventions by many public health institutions
[10-12], although several agencies explicitly opted against
the GRADE approach [13]. A working group, which
was established by the European Centre for Disease
Prevention and Control (ECDC), discussed the applica-
tion of GRADE in infectious disease prevention and
control [14].
The Project on a Framework for Rating Evidence in
Public Health (PRECEPT) was initiated by ECDC in
2012 to build upon the work done by this working
group. It aims to define a framework for evaluating and
grading evidence and strength of recommendations in
the field of infectious disease epidemiology, prevention
and control. An important challenge is that PRECEPT,
in contrast to other frameworks in the field of evidence-
based medicine, is not restricted to the appraisal of
interventions. Rather, since relevant information in
the field of application of PRECEPT comes from non-
interventional studies, such as cross-sectional studies,
surveillance systems and case series, it aims at assessing
evidence from intervention as well as non-intervention
studies.
Before the quality of a “body of evidence” consisting of
multiple studies on a certain outcome can be assessed, it
is necessary to evaluate the methodological quality of
the single studies that constitute it. Quality appraisal
tools (QATs) are designed to evaluate the quality of an
individual study. As a first and necessary step, we there-
fore decided to review already existing QATs with re-
spect to their usefulness across a range of commonly
encountered/critical questions in the field of infectious
disease prevention and control.
Methods
Objectives
Given the above-mentioned challenges in appraising
evidence from a great variety of interventional as well as
non-interventional studies, we decided to use a novel
approach to identify QATs which are suitable for the
project. The approach uses relevant questions as starting
point. Against these questions, study designs which are
able to address the questions are mapped. Finally, QATs
addressing the study designs were identified, using a
systematic review as starting point. The approach is
illustrated in Figure 1.
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Figure 1 Review of quality appraisal tools (QATs). The approach starts with questions which are relevant to infectious disease epidemiology,
prevention and control. Study designs are matched against these questions, followed by identification of QATs.
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ing objectives:
1) To identify relevant questions which are commonly
addressed during decision-making processes in the
field of infectious disease prevention and control.
2) To map appropriate study designs to these
questions.
3) To identify and characterize existing quality
appraisal tools (QATs) which match the respective
study designs and are useful in the context of
infectious disease prevention and control.
Scope and definitions
Prerequisite for the conduct of a review on QATs is to
define the meaning of the term “quality”. According to
the Agency for Healthcare Research and Quality (AHRQ),
“methodological quality” can be defined as the extent to
which a study’s design, conduct, and analysis has mini-
mized selection, measurement, and confounding biases
[15,16]. Thereby, this definition refers to internal validity
of a study or risk of bias [16]. This perspective is also used
by other public health agencies, such as the Canadian
Agency for Drugs and Technologies in Health (CADTH),
which defines methodological quality as “risk of bias” or
“internal validity” [17]. However, it is often of equal
importance to examine external validity, defined as the
degree to which results of a study may be generalized to
other groups or populations [18]. Therefore, some QATs
commonly employed are also concerned with externalvalidity. For the purposes of this study, we adopted an
approach that considers both internal and external valid-
ity: We primarily focused on risk of bias but highlighted
where QATs also addressed external validity.
It is crucial to separate methodological quality, that is,
the quality of the design, conduct and analysis of a study,
from transparency and completeness of reporting [19],
since it has been shown that studies which have similar
reporting quality may be different regarding methodo-
logical quality [20]. Therefore, consensus statements and
related checklists, which aim to increase the quality of
reporting but do not primarily assess the quality of the
underlying study, such as CONSORT for randomized
trials [21] or STROBE for observational studies [22], were
not considered for this review. According to the definition
used by the CADTH report [17], quality appraisal tools
(QATs) are applied to transparently evaluate the quality of
individual studies.
Identification of relevant questions and study designs
The project team began with the development of a draft
matrix, which comprised the potentially relevant ques-
tions grouped in domains. The initial starting point for
the list of questions was the Standard Operating Proced-
ure (SOP) of the German Standing Committee on Vacci-
nations [23]. This document was used as starting point
since the SOP contains a comprehensive list of questions
relevant for evidence appraisal and decision making in
the field of infectious disease prevention, with a particu-
lar focus on vaccination, that has been developed by a
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of an international expert workshop [10]. This matrix was
circulated among the authors for comments and sugges-
tions, leading to the identification of additional questions.
Four authors (TH, AT, ER and OW) developed a proposal
for grouping of questions in domains. This proposal
was again circulated among the authors for suggestions
and comments.
In the second step of matrix building, each of the
scientists involved was asked to map study designs
against the identified questions. All types of study de-
signs (quantitative and qualitative research) were consid-
ered. To define the study designs, we primarily used the
list provided by the NICE Public Health methods man-
ual [13]. In the third step, this list of questions and study
designs was supplemented with appropriate QATs, which
were identified as described below (Figure 1).
Identification of QATs
As a starting point for our approach, a current (publica-
tion date: July 2012) systematic review on reviews on
QATs [17] was used. The rationale behind this approach
was to apply an efficient and time-saving strategy. The
QATS identified in this report were considered for the
matrix. Additionally, we used this systematic review [17]
as the basis for snowballing techniques, i.e. pursuing
references of references [24] to identify other potentially
relevant systematic reviews of QATs. This process led to
the identification of further seven systematic reviews
[16,19,25-29]. The resulting body of a total of eight
systematic reviews [16,17,19,25-29] of QATs was then
screened for relevant QATs which addressed at least
one of the identified study designs. These QATs were
considered for the matrix.
QATs which met the inclusion criteria as given below
were extracted from these reviews. However, since QATs
identified by this approach covered only a minority of
questions and designs, we asked members of the study
team to name additional tools.
Eligibility criteria for QATs
According to the above-mentioned definitions [16,17],
a tool was defined to be a QAT if it is intended to
appraise the methodological quality (internal validity)
of a study.
Each identified QAT was evaluated by two independ-
ent reviewers (T.H. and A.T.) for its eligibility. QATs
were included if they fulfilled the following a priori
defined inclusion criteria:
1) The tool has been published (either in a journal or
on a website).
2) The tool covers at least one study design of the
matrix.3) The tool is suitable for rating study quality, that is, a
list of methodological items is given that have to be
answered or assessed.
4) The tool was developed for general use (not for a
specific study).
5) The tool has undergone at least one validation
procedure (e.g., inter-rater reliability).
The following example might illustrate this approach.
The Cochrane Collaboration’s tool for assessing risk of
bias fulfilled all five inclusion criteria: 1) The tool has
been published in the Cochrane Handbook and in a
journal article. 2) The tool covers randomized controlled
trials being one of the relevant study designs. 3) Study
quality (or risk of bias) is rated by addressing six do-
mains (selection bias, performance bias, detection bias,
attrition bias, reporting bias, other bias) and making the
judgement of “low risk of bias”, “high risk of bias” or
“unclear risk of bias”. 4) The tool was developed to be
applied to all randomized controlled trials. 5) The tool
has been validated regarding interrater reliability (for
details, see Appendix B).
The reviewers made exceptions from these eligibility
criteria to arrive at a more comprehensive list of QATs,
in particular when there was a lack of other QATs for a
defined study design or when a QAT was very frequently
used in public health. In such cases, a note was added to
the description of the QAT (see below).
The following example might illustrate such an excep-
tion. The checklist developed by the Cochrane Effective
Practice and Organization of Care (EPOC) group did
only fullfil three out of five of the inclusion criteria: It
has not been published so far (criterium 1) and has not
been validated (criterium 5). However, the QAT was in-
cluded in our matrix since it is very frequently used in
public health.
Data extraction for QATs
From each publication of a QAT, we extracted the
following information:
1) For which study design(s) is the instrument intended
to be used?
2) What was the primary purpose for which the
instrument was developed?
3) How many questions does the instrument comprise?
4) Are questions grouped in domains?
5) What are the main contents of the questions (or,
which domains are covered)?
6) What types of questions are used (e.g., predefined,
open)?
7) Does the instrument include a quality summary score?
8) If 7) is answered with yes: how is the score
calculated?
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to apply the tool on average?
10) How was the instrument validated?
11) What was the main result of the validation
procedure?
Results of this data extraction were summarized in an
abstract for each QAT.
Analysis
The extracted information on relevant questions, study
designs and QATs was analyzed as follows:
 A matrix was constructed that mapped study
designs to relevant questions, and QATs to study
designs.
 The data extracted from the original descriptions of
the QATs was summarized in one abstract per QAT.
 The number of questions/items of each QAT,
information on the structure (checklist, scale,
summary score) and validation of each QAT was
summarized across all QATs.
Results
Relevant questions
We identified a total of 20 questions of potential rele-
vance during decision-making processes in the field of
infectious disease epidemiology, prevention and control.
These questions were grouped into 6 domains (A – F):
Domain A: characteristics of the pathogen
What are the …
1) Characteristics of the pathogen (pathogenicity,
virulence, reservoir)?
2) Subtypes, serotypes and local epidemiology (incl.
seasonality) of the pathogen?
3) Modes of transmission?
Domain B: burden of disease
What is/are the …
4) Incidence of the disease?
5) Prevalence/seroprevalence of the disease/pathogen?
6) Consequences or sequelae of the disease:6.1 Hospitalization rate?
6.2 Mortality?
6.3 Complication rate (acute)?
6.4 Rate of disabilities (chronic)?
7) Perception of the disease in the target population?
Domain C: diagnosis
What is the …
8) Sensitivity of tests?
9) Specificity of tests?
Domain D: risk factors
10) What are risk factors for …
10.1 Transmission?10.2 Colonisation?
10.3 Infection/disease?
10.4 Exacerbation/complications?
Domain E: intervention
11) What are effects of the intervention at the
individual/population level in terms of …
11.1 Efficacy (under controlled conditions)?
11.2 Direct/indirect/overall effectiveness (under
uncontrolled conditions)?
11.3 Surrogate markers for 11.1 and 11.2?
11.4 Risk of adverse events/harms?
Domain F: implementation of intervention (or
diagnostic measure) in the population
Is the intervention (or diagnostic measure)…
12) Feasible to implement?
13) Cost-effective?
14) Acceptable to most relevant stakeholders?
15) Equitable or equity-enhancing?
What are…
16) Enablers and barriers to success?
17) Coverage rates needed to induce positive
population level effects?
How …
18) Shall the advice be communicated (incl. the hard to
reach)?
19) Shall population preferences be weighted and
valued?
20) Effective and implementable are alternative
measures?
Study designs
The following 26 different study designs (grouped into
six categories) were considered to be potentially able to
inform the relevant questions:
I) Quantitative studies - experimental:
a) Randomized controlled trial (RCT)
b) Cluster-randomized controlled trial (cRCT)
c) Non-randomized controlled trial (NRCT) and
other quasi-experimental study
d) Controlled before-and-after study
II)Quantitative studies - observational:
e) Uncontrolled before-and-after study
f ) Interrupted time series (ITS)
g) Cohort study
h) Case-control study
i) Ecological study (correlation study)
j) Cross-sectional study/Surveillance
k) Self-controlled case series
l) Case series
m) Case report (single case study)
III) Qualitative studies:
n) Document analysis
o) Focus groups
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q) Observation and participant observation
r) Process evaluation
IV) Economic studies/Mathematical modeling studies:
s) Cost-benefit analysis
t) Cost-consequence analysis
u) Cost-effectiveness analysis
v) Cost-utility analysis
w) Non-economic modeling study
V) Diagnostic test accuracy studies
VI) Non-epidemiological evidence
x) Animal study
y) Other laboratory study
For definitions of the study designs, see Appendix A
(Glossary of study designs).
Quality appraisal tools (QATs)
The review process led to the identification of a total of
21 QATs [30-50]. The selection process is illustrated as a
flow chart in Figure 2. A total of seven QATs could be
extracted from the above-mentioned reviews and met
criteria for eligibility. These seven QATs, however, cov-
ered only a minority of questions and study designs
addressed in the matrix. Discussions in the project team
identified an additional 14 relevant QATs, leading to a
total of 21 QATs. According to the six categories of rele-
vant study designs described above, four of these QATs
are applicable to experimental quantitative study designs,1 systemaƟc
systemaƟc 
15 QATs sc
7 QATs el
21 QATs in
4 QATs for
experimental
quanƟtaƟve
studies
(Group I) 
11 QATs for
observaƟonal
quanƟtaƟve
studies
(Group II)
2 QATs for
qualitaƟve
studies
(Group III)
Figure 2 Flow chart: identification and selection of quality appraisal televen are intended for observational quantitative studies,
two for qualitative studies, three for economic studies,
one for diagnostic test accuracy studies and one for animal
studies (Figure 2).
In Table 1, these QATs were mapped against the re-
spective questions and study designs. To the majority of
the 20 questions, more than one study design could be
matched. For example, question 11 (What are the effects
of intervention?) can be addressed by 10 different study
designs, ranging from experimental studies (RCT, cluster-
randomized trial) to observational studies (case-control
study, cohort study etc.). For some questions, however,
only one study design was judged to be suitable: Question
5 (What is the prevalence of the disease?) can only be ad-
dressed by cross-sectional studies. Similar observation was
made when QATs were matched to study designs. For the
majority of study designs, we found more than one QAT
to be applicable. For example, cohort studies and case-
control studies can be assessed by five different QATs
each. However, for some designs, such as animal studies
and cost-utility analyses, we identified only one eligible
QAT per study design.
The following two examples should illustrate the
approach of the matrix:
 For the research question “Is neonatal sepsis a risk
factor for neurodevelopmental delay?”, the user
would choose domain D, question no. 10 (risk
factors). Five different study designs are suggested to review of
reviews
reened
igible
14 QATs idenƟfied by
team discussions
cluded
8 QATs excluded
because they did not
meet inclusion criteria
3 QATs for
economic
studies
(Group IV) 
1 QAT for
diagnosƟc
studies
(Group V)
1 QAT for
animal
studies
(Group VI)
7 systemaƟc reviews
idenƟfied by
snowballing
techniques
ools (QATs) during the review process.
Table 1 Tabulation of questions, respective study designs and quality appraisal tools which are relevant in the field of
infectious disease epidemiology, prevention and control
Domain1 No. Question Study design Quality appraisal tools (Reference)2
A 1 Characteristics of the pathogen? Laboratory study Van der Worp [37]3
A 2 Subtypes, serotypes and local epidemiology
of the pathogen?
Laboratory study Van der Worp [37]
Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
A 3 Modes of transmission? Animal study Van der Worp [37]
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
Case series Cho [30]
Case-control study Downs [31], SIGN [41], Cho [30], EPHPP
[38], NOS [44]
B 4 Incidence of the disease? Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
B 5 Prevalence/seroprevalence of the disease? Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
B 6 Consequences or sequelae of the disease
(hospitalization/mortality/complications/
disabilities)?
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
Case series Cho [30]
Case report Cho [30]
B 7 Perception of the disease in the target
population?
Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
Focus groups NICE [48], CASP [36]
Interview study
C 8 Sensitivity of tests? Diagnostic test accuracy study SIGN [42]
C 9 Specificity of tests? Diagnostic test accuracy study SIGN [42]
D 10 Risk factors (for transmission/colonization/
infection/disease/exacerbation/
complication)?
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
Case-control study Downs [31], SIGN [41], Cho [30], EPHPP
[38], NOS [44]
Ecological study NICE [47]
Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
Animal study Van der Worp [37]
E 11 Effects of intervention (in terms of efficacy/
effectiveness/surrogate markers/adverse
events/harms)?
Controlled before-and-after study Downs [31], NICE [46], EPHPP [38]
RCT Cochrane [35], Downs [31], SIGN [39],
NICE [46], EPHPP [38]
NRCT Downs [31], NICE [46], EPHPP [38]
Cluster-randomized trial Downs [31], NICE [46], EPHPP [38]
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
Case-control study Downs [31], SIGN [41], Cho [30], EPHPP
[38], NOS [44]
Uncontrolled before-and-after study Downs [31], NICE [46], EPHPP [38]
Ecological study NICE [47]
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Table 1 Tabulation of questions, respective study designs and quality appraisal tools which are relevant in the field of
infectious disease epidemiology, prevention and control (Continued)
Interrupted time series EPOC [50], EPHPP [38]
Self-controlled case series Cho [30], NOS [44], SIGN [41]
F 12 Feasible to implement? Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
Focus groups NICE [48], CASP [36]
Interview study
F 13 Cost-effectiveness of the intervention? Cost-effectiveness (-benefit,
-consequence) analysis
SIGN [43], NICE [49], QHES [34]
Cost-utility analysis QHES [34]
F 14 Acceptable to stakeholders? Focus groups NICE [48], CASP [36]
Interview study
Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
F 15 Equitable? Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
F 16 Enablers/barriers to success? Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
Interview study (observation) NICE [48], CASP [36]
Document analysis
Focus groups
Process evaluation
F 17 Coverage rates for positive population level
effects?
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
Non-economic modeling study SIGN [43], NICE [49]
F 18 Communication of advice? RCT Cochrane [35], Downs [31], SIGN [39],
NICE [46], EPHPP [38]
NRCT Downs [31], NICE [46], EPHPP [38]
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
Cross-sectional study Al-Jader [33], Loney [32], Hoy [45], Cho
[30], NICE [47]
Focus groups NICE [48], CASP [36]
Interview study
F 19 Weighing and valuing of population
preferences?
Cross-sectional study Al-Jader [33], Loney [32], Hoy [5], Cho
[30], NICE [47]
Focus groups NICE [48], CASP [36]
Interview study
F 20 Effectiveness of alternative measures? Controlled before-after study Downs [31], NICE [46], EPHPP [38]
RCT Cochrane [35], Downs [31], SIGN [39],
NICE [46], EPHPP [38]
NRCT Downs [31], NICE [46], EPHPP [38]
Cluster-randomized trial Downs [31], NICE [46], EPHPP [38]
Cohort study Downs [31], SIGN [40], Cho [30], EPHPP
[38], NOS [44]
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Table 1 Tabulation of questions, respective study designs and quality appraisal tools which are relevant in the field of
infectious disease epidemiology, prevention and control (Continued)
Case-control study Downs [31], SIGN [41], Cho [30], EPHPP
[38], NOS [44]
Uncontrolled before-after study Downs [31], NICE [46], EPHPP [38]
Ecological study NICE [47]
Interrupted time series EPOC [50], EPHPP [38]
Self-controlled case series Cho [30], NOS [44], SIGN [41]
1Domains A-F refer to the following domains of questions described under Results: A – Characteristics of the pathogen; B – Burden of disease; C – Diagnosis;
D – Risk factors; E – Intervention; F – Implementation of intervention.
2See footnote 2 of Table 2 for complete names of the included QATs.
3For alternative QATs for animal studies, see the review by Krauth et al. [51] published after completion of our literature search.
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ecological study, cross-sectional study and animal
study. If the user has identified a cohort study,
he/she is guided by the matrix to use one out of five
different QATs to assess the methodological quality
of the study (Downs, SIGN, Cho, EHPP or NOS).
 For the research question “What is the prevalence of
neonatal sepsis?”, the user would choose domain
B, question 5 (prevalence). He/she is guided to
cross-sectional studies as the appropriate study
design. For methodological quality appraisal of this
type of studies, five QATs are suggested (Al-Jader,
Loney, Hoy, Cho and NICE).
Table 2 shows a cross-tabulation of all QATs (rows)
against all study designs (columns) which were consid-
ered. The table is intented to guide users who are look-
ing for an appropriate QAT for a particular study with a
given design. Study designs are ordered alphabetically in
columns from the left-hand to the right-hand side. QATs
are shown in the order of appearance in Table 1 from
top to bottom. Nine QATs are only applicable to a single
study design, whereas 12 QATs can be used for more
than one study design.
In Table 3, basic information is provided regarding the
content and validation of QATs. QATs are shown in the
order of their appearance in Table 1. For each QAT, the
number of questions/items is summarized. Furthermore,
information is given whether the QAT is a checklist or a
scale, whether it has a summary score and whether it
has been validated so far. QATs had six to 28 items, with
the majority having more than ten items. Five QATs
were scales, while the remaining 16 were checklists. Six
of the QATs had a summary quality score. Fourteen
QATs had undergone at least one validation procedure.
The approach, content and validation of each QAT are
described in detail in the related Appendix B.
Discussion
So far, reviews of QATs have been conducted by using the
study types they cover as a basis. For our methodologicalstudy we chose a new strategy and applied for the first
time a question-based approach. Our study is intended to
represent a starting point for comprehensive evidence-
based decision making in infectious disease prevention
and control through the formulation of a broad set of
questions and matching these questions to the most
appropriate evidence in terms of study design followed by
assessing study quality.
One has to keep in mind, however, that there is no dir-
ect relation between a research question and a QAT. Ra-
ther, QATs are constructed to assess the methodological
quality of a study which has a given study design. Accord-
ing to the key features of different study designs, different
sources of bias arise. For example, the effectiveness of an
intervention can be assessed by randomized controlled
studies or by case-control studies. In the randomized con-
trolled studies, inadequate blinding of participants is an is-
sues that can be assessed by an appropriate QAT (e.g., the
Cochrane risk of bias tool). However, if the same interven-
tion question is addressed by a case-control study, blind-
ing of participants does not play a role. Rather, other
specific issues of case-control studies, such as adequate
control selection, become important and are captured by
appropriate QATs (e.g., the Newcastle-Ottawa Scale).
The strengths of our approach include the development
of a comprehensive picture which covers the full process
from question development to quality appraisal. Through
multiple rounds of discussions and consultations, we iden-
tified a total of 20 questions considered most important
for evaluating and grading evidence and strength of recom-
mendations in the field of infectious disease epidemiology,
prevention and control. The majority of these can be ad-
dressed by experimental and observational study designs.
For some questions the appraisal of non-epidemiological
evidence was needed. We therefore also considered non-
epidemiological study designs, such as qualitative studies.
This type of studies should be considered if epidemio-
logical studies are unlikely to provide useful information
for a given research question. For example, as shown in
Table 1 under Domain F, question 19, for weighing and
valuing of population preferences, the conduct of focus
Table 2 Cross-tabulation of quality appraisal tools (QATs) against study designs
QAT
(Reference)1
Animal
study
Before-and-after
study (controlled)
Before-and-
after-study
(uncontrolled)
Case-control
study
Case
report
Case
series
(Cluster)
rRCT
Cohort
study
Cost-effectiveness
(-benefit,
-consequence)
analysis
Cost-utility
analysis
Cross-sectional
study
Diagnostic test
accuracy study
Van der Worp [37] X
NICE (qualitative) [48]
CASP [36]
SIGN (diagnostic) [42] X
Cho [30] X X X X X X X X
Hoy [45] X
Al-Jader [33] X
SIGN (cohort) [40] X
NOS [44] X X
EPOC [50]
SIGN (case-control) [41] X
NICE (intervention) [46] X
Cochrane [35]
SIGN (RCT) [39]
NICE (correlation) [47]
Downs et al. [31] X X X X X
Loney et al. [32] X
QHES [34] X X
EPHPP [38] X X X X X
SIGN (economic) [43] X
NICE (economic) [49] X
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Table 2 Cross-tabulation of quality appraisal tools (QATs) against study designs (Continued)
QAT
(Reference)1
Document
analysis
Ecological
study
Focus
groups
(Individually)
RCT
Interrupted
time series
Interview study
(Observation study)
Laboratory
study
Non-economic
modeling study
nRCT Process
evaluation
Self-controlled
case series
Van der Worp [37] X
NICE (qualitative) [48] X X X X
CASP [36] X X X X
SIGN (diagnostic) [42]
Cho [30] X X X
Hoy [45]
Al-Jader [33]
SIGN (cohort) [40]
NOS [44] X
EPOC [50] X
SIGN (case-control) [41] X
NICE (intervention) [46] X X
Cochrane [35] X
SIGN (RCT) [39] X
NICE (correlation) [47] X
Downs et al. [31] X X
Loney et al. [32]
QHES [34] X
EPHPP [38] X X X
SIGN (economic) [43] X
NICE (economic) [49] X
1Complete names of the included QATs (in the order of appearance): Van der Worp: Aspects of study quality to be reported; NICE (qualitative): Quality appraisal checklist: qualitative studies; CASP: Critical appraisal
skills programme tools; SIGN (diagnostic): Scottish Intercollegiate Guidelines Network (SIGN) checklist 5 (diagnostic studies); Cho: Methodologic quality instrument; Hoy: Tool to assess risk of bias in prevalence studies;
Al-Jader: Quality scoring system for epidemiological surveys of genetic disorders; SIGN (diagnostic): Scottish Intercollegiate Guidelines Network (SIGN) checklist 3 (cohort studies); NOS: Newcastle-Ottawa Scale; EPOC:
Cochrane Effective Practice and Organization of Care (EPOC) Groups risk of bias tool for interrupted time series; SIGN (case-control): Scottish Intercollegiate Guidelines Network (SIGN) checklist 4 (case-control studies);
NICE (intervention): National Institute for Health and Care Excellence quality appraisal checklist for quantitative intervention studies; Cochrane: Cochrane risk of bias tool for RCTs; SIGN (RCT): Scottish Intercollegiate
Guidelines Network (SIGN) checklist 2 (RCTs); NICE (correlation): National Institute for Health and Care Excellence quality appraisal checklist for quantitative studies reporting correlations and associations; Downs:
Checklist for the assessment of the methodological quality of randomized and non-randomized studies of health care interventions; Loney: Guidelines for critically appraising studies of prevalence or incidence of a
health problem; QHES: Quality of Health economic studies instrument; EPHPP: Effective Public Health practice projects quality assessment tool for quantitative studies; SIGN (economic): Scottish Intercollegiate
Guidelines Network (SIGN) checklist 6 (economic studies); NICE (economic): National Institute for Health and Care Excellence quality appraisal checklist for economic evaluations.
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Table 3 Characteristics of included quality appraisal tools
(QATs)
QAT
(Reference)
No. of
questions
or items
Checklist
(C) or
scale (S)?
Summary
score?
(yes/no)
Validation?
(yes/no)
Van der Worp [37] 9 C No No
NICE [47] 20 C No No
SIGN [39] 10 C No yes
Cho [30] 24 C yes Yes
Hoy [45] 10 C No Yes
Al-Jader [33] 9 S Yes Yes
SIGN [40] 16 C No Yes
NOS [44] 8 S No Yes
EPOC [50] 7 C No No
SIGN [41] 13 C No Yes
NICE [46] 27 C No No
Cochrane [35] 6 C No Yes
SIGN [42] 28 C No Yes
Loney [32] 8 S Yes Yes
Downs [31] 27 S Yes Yes
EPHPP [38] 20 C Yes Yes
CASP [36] 10 C No No
NICE [48] 15 C No No
SIGN [43] 20 C No Yes
NICE [49] 19 C No No
QHES [34] 16 S Yes Yes
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http://www.biomedcentral.com/1471-2288/14/69groups might be appropriate. This will be particularly
important in a situation when no prior information is
available regarding such preferences and the researcher
has to generate new hypotheses about them. Other relevant
questions which can be answered by qualitative research
include those about enablers and barriers to the success of
an intervention (Domain F, question 16).
The first step in the identification of appropriate
appraisal instruments was to consider review papers of
QATs. The rationale behind this approach was to apply
an efficient and time-saving strategy. We hereby decided
to start with a very recent systematic review and to
complement its findings with those from other system-
atic reviews, using snowballing techniques. Many of the
published instruments focus on experimental study
designs, but do not cover other relevant study designs,
such as diagnostic studies or qualitative studies. There-
fore, we had to use a second approach (expert con-
sultations) to fill the gaps in our question matrix. In
particular, the latter approach helped to identify QATs
for study designs such as (controlled) before-and-after-
studies and interrupted time series. These designs havein common that they are widely used in public health
research, but are not as intensively reflected in the trad-
ition of evidence-based medicine. The QATs identified
and included in the matrix showed large variability re-
garding their length and complexity. Only two-thirds of
the QATs were validated by the authors or other investi-
gators. Moreover, validation procedures differed mark-
edly, making comparisons regarding the validity of the
QATs difficult.
During recent years, it has been intensively discussed
whether or not QATs should have a summary score [52].
For this review, we considered QATs irrespective of
whether they had such a score. However, for a compari-
son of evidence assessments based on different QATs for
different study designs, a summary score might be useful.
Whether or not the use of a score in a QAT is necessary
for further development of PRECEPT will be one aspect
to be discussed and evaluated later.
Limitations of our approach mainly regard the identi-
fication of appropriate QATs. Whereas for some very
common study designs QATs could easily be identified
based on systematic reviews, this was not feasible for
other study designs and had to be done by team discus-
sions. Furthermore, combining different QATs across
different study designs may lead to problems in prac-
tice. It should therefore be evaluated whether “pack-
ages” of QATs developed within one framework (e.g.
NICE (15)) may be preferable. Finally, one has to keep
in mind that the choice of QAT may exert a significant
influence on the result of the respective systematic
review. This has been shown recently in a study demon-
strating that results of sensitivity analyses according to
study quality show considerable variability depending
on which QAT was used to assess study quality in a
meta-anaysis [53].
Conclusions
Our question-centered review is the first that assembles
QATs for all study designs considered relevant in the
field of infectious diseases. Thereby, it adds to what is
already known on QATs by providing a systematic over-
view on this topic, including a description and assess-
ment of the included QATs. Our primary goal was to
inform and establish the basis for the development of the
PRECEPT evidence assessment framework. In addition,
we provide an inventory of questions, study designs and
quality appraisal tools to support public health researchers
and authorities in assessing evidence when developing
recommendations for infectious disease prevention and
control. The inventory can easily be supplemented if new
tools are published in the future. Next steps will be to in-
tegrate these findings into the PRECEPT framework, and
to define a methodology how to assess bodies of evidence
within the framework.
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Appendix A
Glossary of study designs
Definitions were derived from the NICE manual [13] and
additional references [18,54-57].
 Animal study/other laboratory study
A study in a population of laboratory animals that
often uses conditions of animals analogous to conditions
in humans to model processes that occur in human
populations (analogous for other laboratory studies using
cell culture etc).
 Before-and-after study (controlled: experimental;
uncontrolled: observational)
An approach where the dependent variables are mea-
sured before and after an intervention has been deliv-
ered. The intervention can either be delivered by the
investigator or by others (experimental vs observational
before-and-after study).
 Case-control study
A comparative observational study in which the inves-
tigator selects people who have an outcome of interest
(for example, developed a disease) and others who have
not (controls), and then collects data to determine previ-
ous exposure to possible causes.
 Case report
Detailed description of a single patient or clinical case.
 Case series
A collection of patients with common characteristics
used to describe aspects of a disease, diagnosis, treat-
ment and prognosis.
 Cohort study
An observational study in which a group of people is
observed over time in order to see who develops the
outcome of interest.
 Cost-benefit analysis
An analysis which investigates whether all benefits
outweigh all costs of an intervention. Cost-consequence analysis
An analysis which contrasts the resources and costs to
the results of an activity, usually in table form.
 Cost-effectiveness analysis
An analysis which asks how one can maximize health
(measured as clinical outcome) for available resources.
 Cost-utility analysis
A form of economic evaluation in which the outcomes
of alternative procedures or programs are expressed in
terms of a single “utility-based” unit of measurement.
 Cross-sectional study
An observational study in which the source population
is examined to see what proportion has the outcome of
interest, or has been exposed to a risk factor of interest,
or both, at a fixed time point.
 Diagnostic test accuracy study
A study which determines the sensitivity and/or speci-
ficity of a diagnostic test or measure.
 Document analysis
A quantitative or qualitative approach that consists of
the systematic reading and compiling of a body of texts,
images, and symbolic matter.
 Ecological study
An observational study in which the units of ana-
lysis are populations or groups of people rather than
individuals.
 Focus groups
A sample of people (usually a relatively homogeneous
group drawn by purposive sampling) brought together
to discuss a topic or issue with the aim of ascertaining
the range and intensity of their views rather than arriv-
ing at a consensus.
 Interrupted time series
An approach in which multiple (more than two) obser-
vations are made on the same individuals, or groups of
individuals, over time. Some authors demand that a de-
fined number of data points have to be assessed before
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http://www.biomedcentral.com/1471-2288/14/69and after the intervention of interest (e.g., three before
and three after).
 Interview study (qualitative)
A qualitative method of data collection where partici-
pant’s views are elicited via verbal interviews, consisting
of mostly open-ended questions.
 Non-economic modeling study (mathematical
model)
A study which uses a representation of a system,
process, or relationship in mathematical form in which
equations are used to simulate the behavior of the sys-
tem or process under study (use of Bayesian or frequen-
tist methods possible).
 Non-randomized controlled trial (NRCT)
An experimental study in which participants are allo-
cated to receive either intervention or control (or com-
parison intervention) but the allocation is not randomized.
 Observation/participant observation
A qualitative methodology where the researcher is (or
pretends to be) a member of the group being studied.
 Process evaluation
The systematic collection of information on a pro-
gram’s inputs, activities, and outputs, as well as the
program’s context and other key characteristics.
 Randomized controlled trial (RCT)/cluster-
randomized controlled trial
An experimental study in which participants (or clus-
ters) are randomly allocated to receive either interven-
tion or control.
 Self-controlled case series
A study design which solely uses cases that function
at the same time as their own controls by estimating
the relative incidence of an acute event in their risk
period (e.g. defined as during or after exposure) com-
pared to the risk of an acute event in their control
period.
Appendix B
Description of included quality appraisal tools (QATs)
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